Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 6,415.00
+108.00 (1.71%)
Oct 29, 2026, 11:30 AM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.22T JPY in the quarter ending June 30, 2026, with 10.23% growth. This brings the company's total for the last twelve months to 4.62T, up 4.57% year-over-year. In the fiscal year ending March 31, 2026, Takeda Pharmaceutical Company had annual revenue of 4.51T, down -1.66%. That makes Takeda Pharmaceutical Company the 469th largest company in the world by revenue and 43rd in Japan.
Revenue (ttm)
4.62T
Revenue Growth
+4.57%
P/S Ratio
2.18
Revenue / Employee
98.21M
Employees
47,029
Market Cap
10.24T
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full TYO:4502 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.51T | -75.83B | -1.66% |
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | 326.69B | 18.45% |
| Mar 31, 2018 | 1.77T | 38.48B | 2.22% |
| Mar 31, 2017 | 1.73T | -75.33B | -4.17% |
| Mar 31, 2016 | 1.81T | 29.55B | 1.66% |
| Mar 31, 2015 | 1.78T | 86.14B | 5.09% |
| Mar 31, 2014 | 1.69T | 134.42B | 8.63% |
| Mar 31, 2013 | 1.56T | 48.34B | 3.20% |
| Mar 31, 2012 | 1.51T | 89.55B | 6.31% |
| Mar 31, 2011 | 1.42T | -46.58B | -3.18% |
| Mar 31, 2010 | 1.47T | -72.37B | -4.70% |
| Mar 31, 2009 | 1.54T | 163.53B | 11.90% |
| Mar 31, 2008 | 1.37T | 69.64B | 5.34% |
| Mar 31, 2007 | 1.31T | 92.96B | 7.67% |
| Mar 31, 2006 | 1.21T | 89.25B | 7.95% |
| Mar 31, 2005 | 1.12T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Eisai | 857.06B |
| Shionogi & | 563.21B |
| Sumitomo Pharma | 474.79B |
| Towa Pharmaceutical | 279.94B |
| Sawai Group Holdings | 203.79B |
| Tsumura & Co. | 199.23B |
| Nippon Shinyaku | 180.29B |
| Mochida Pharmaceutical | 122.04B |
Takeda Pharmaceutical Company News
- 3 days ago - Takeda to seek Japan approval for gastric cancer drug next year - Reuters
- 5 days ago - Takeda announces Phase 3 G-HOPE-001 study met primary endpoints - TheFly
- 5 days ago - Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study - Business Wire
- 9 days ago - Takeda's ENTYVIO Treat-To-Target Trial Reduces UC Complication Risk By Nearly 70%; Stock Down - Nasdaq
- 9 days ago - Takeda Reports Positive New Data Of VERDICT Phase 4 ENTYVIO Trial In Ulcerative Colitis - Nasdaq
- 9 days ago - First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication - Business Wire
- 14 days ago - Takeda Launches ORZEYFUL For Narcolepsy Type 1 In Japan, China; Stock Up - Nasdaq
- 14 days ago - Takeda’s ORZEYFUL launches in Japan and China - TheFly